Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates

被引:84
作者
Gillespie, SH [1 ]
Basu, S [1 ]
Dickens, AL [1 ]
O'Sullivan, DM [1 ]
McHugh, TD [1 ]
机构
[1] UCL, Ctr Med Microbiol, London NW3 2PF, England
关键词
fluoroquinolones; mycobacteria; quinolones; M; fortuitum;
D O I
10.1093/jac/dki191
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: Fluoroquinolones have found a place in the management of mycobacterial diseases including tuberculosis. It has been previously shown that subinhibitory concentrations of quinolones increase the mutation rate in Escherichia coli and staphylococci. The purpose of this study is to extend this observation to mycobacteria and to quantify mutation rates. Methods: The mutation rate in Mycobacterium fortuitum to ciprofloxacin, levofloxacin, moxifloxacin, rifampicin, erythromycin and gentamicin resistance was determined when grown with and without various sub-MIC concentrations of ciprofloxacin. Results: M. fortuitum exposed to 1/2 MIC ciprofloxacin had an increase in the mutation rate of between 72- and 120-fold when selected on quinolones or other anti mycobacterial antibiotics. Smaller, but significant increases in mutation rate were seen when the organism was exposed to lower concentrations (1/4 MIC and 1/8 MIC). Conclusions: These data show that sub-MIC concentrations of fluoroquinolone significantly increase mutation rates and these data suggest that care must be taken to ensure that bacteria are not exposed to subinhibitory concentrations when adding quinolones to a regimen used to treat mycobacterial infection.
引用
收藏
页码:344 / 348
页数:5
相关论文
共 39 条
[1]   A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].
Andries, K ;
Verhasselt, P ;
Guillemont, J ;
Göhlmann, HWH ;
Neefs, JM ;
Winkler, H ;
Van Gestel, J ;
Timmerman, P ;
Zhu, M ;
Lee, E ;
Williams, P ;
de Chaffoy, D ;
Huitric, E ;
Hoffner, S ;
Cambau, E ;
Truffot-Pernot, C ;
Lounis, N ;
Jarlier, V .
SCIENCE, 2005, 307 (5707) :223-227
[2]  
[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
[3]   Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis [J].
Billington, OJ ;
McHugh, TD ;
Gillespie, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1866-1869
[4]   DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis [J].
Boshoff, HIM ;
Reed, MB ;
Barry, CE ;
Mizrahi, V .
CELL, 2003, 113 (02) :183-193
[5]  
Campbell I, 2000, THORAX, V55, P210
[7]   High frequency of mutator strains among human uropathogenic Escherichia coli isolates [J].
Denamur, E ;
Bonacorsi, S ;
Giraud, A ;
Duriez, P ;
Hilali, F ;
Amorin, C ;
Bingen, E ;
Andremont, A ;
Picard, B ;
Taddei, F ;
Matic, I .
JOURNAL OF BACTERIOLOGY, 2002, 184 (02) :605-609
[8]   DNA gyrase, topoisomerase IV, and the 4-quinolones [J].
Drlica, K ;
Zhao, XL .
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1997, 61 (03) :377-+
[9]  
DYE C, 2000, P ROY SOC LOND B BIO, V267, P1
[10]   FAILURE OF DRUG PENETRATION AND ACQUISITION OF DRUG-RESISTANCE IN CHRONIC TUBERCULOUS EMPYEMA [J].
ELLIOTT, AM ;
BERNING, SE ;
ISEMAN, MD ;
PELOQUIN, CA .
TUBERCLE AND LUNG DISEASE, 1995, 76 (05) :463-467